Puma Biotechnology (NASDAQ:PBYI – Get Free Report) posted its earnings results on Thursday. Puma Biotechnology Stock PerformancePBYI traded up $0.79 on Friday, reaching $8.91. Also, Director Jay M. Moyes sold 22,000 shares of Puma Biotechnology stock in a transaction that occurred on Friday, June 12th. TD Cowen raises Puma Biotechnology price targetPuma Biotechnology Company Profile(Get Free Report)Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Read MoreReceive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.